Appendix D - Dossier (PDF) - Tera

date: 20–JUL–2005
5. Toxicity Substance ID: 71–43–2
______________________________________________________________________________
Type: Cytogenetic assay
Species: rat Sex: male/female
Strain: Sprague–Dawley
Route of admin.: inhalation
Exposure period: 13 weeks
Doses: 0, 1, 10, 30, 300 ppm (converts to 0, 0.003, 0.033, 0.098,
0.98 mg/l)
Method: other
GLP: no data
Test substance: no data
Remark: Report of a study conducted for the American Petroleum
Institute.
Result: No increase in chromosomal damage was observed at
concentrations of 0.098 mg/l or less. Slight increases in
aberrations were seen at 0.98 mg/l but these were not
statistically significant.
Source: BP Chemicals Ltd LONDON
13–DEC–1996 (321) (490)
Type: Cytogenetic assay
Species: mouse Sex: male/female
Strain: DBA
Route of admin.: inhalation
Exposure period: 4 hours
Doses: 0, 3130 +/–170 ppm (converts to 0, 10.2 +/–0.55 mg/l)
Method: other
GLP: no data
Test substance: no data
Remark: Groups of ten male and eleven female DBA/2 mice were exposed
to benzene. The control group consisted of six animals/sex.
A further group of six males and seven females were injected
intraperitoneally with sodium phenobarbital, twice daily for
3 days prior to benzene exposure. Benzene concentration was
measured at half–hour intervals. Control and exposed mice
were treated with bromodeoxyuridine 1 hour after exposure
and colcemid was injected intravenously 2 hours before
termination. The animals were killed, femurs removed,
marrow flushed out, slides prepared and chromosomal
aberration frequency assessed.
Result: Benzene alone did not increase the frequency of chromosomal
aberrations. Treatment with phenobarbital before benzene
exposure caused a statistically significant increase in
chromatid–type aberrations. This was not seen in control
mice pretreated with phenobarbital.
Source: BP Chemicals Ltd LONDON
13–DEC–1996 (1138)
Appendix D: Benzene SIDS Dossier
– 457/957 –